Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO
Completed · Phase 2
Conditions studied: Retinal Vein Occlusion
In brief
Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
Key facts
- Study ID
- NCT02387788
- Run by
- Aerpio Therapeutics
- People needed
- 16
- Starts
- 2015-01-01
- Expected to finish
- 2017-04-01
- Last updated by the study team
- 2018-06-27
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Wilmer Eye Institute — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.